CN1583063A - Extraction of effective components from frankinscene and its preparation and use - Google Patents
Extraction of effective components from frankinscene and its preparation and use Download PDFInfo
- Publication number
- CN1583063A CN1583063A CN 200410024253 CN200410024253A CN1583063A CN 1583063 A CN1583063 A CN 1583063A CN 200410024253 CN200410024253 CN 200410024253 CN 200410024253 A CN200410024253 A CN 200410024253A CN 1583063 A CN1583063 A CN 1583063A
- Authority
- CN
- China
- Prior art keywords
- olibanum
- effective component
- extraction
- ether
- time
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000605 extraction Methods 0.000 title claims description 29
- 238000002360 preparation method Methods 0.000 title claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 48
- 241000717739 Boswellia sacra Species 0.000 claims abstract description 42
- 239000004863 Frankincense Substances 0.000 claims abstract description 42
- 239000000284 extract Substances 0.000 claims abstract description 35
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 33
- 238000003756 stirring Methods 0.000 claims abstract description 6
- 239000003960 organic solvent Substances 0.000 claims abstract description 5
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract 2
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 16
- 238000001556 precipitation Methods 0.000 claims description 11
- 229960004756 ethanol Drugs 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 5
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 5
- 238000010828 elution Methods 0.000 claims description 5
- 238000001953 recrystallisation Methods 0.000 claims description 5
- 239000012043 crude product Substances 0.000 claims description 4
- 208000006820 Arthralgia Diseases 0.000 claims description 3
- 208000025747 Rheumatic disease Diseases 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000003208 petroleum Substances 0.000 claims description 3
- 230000000552 rheumatic effect Effects 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 6
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 abstract 2
- 239000007788 liquid Substances 0.000 abstract 1
- 238000010298 pulverizing process Methods 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001057584 Myrrha Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A process for extracting the active component from frankincense includes such steps as pulverizing, immersing in organic solvent for extracting three times to obtain liquid extract, concentrating, adding the solution of dicarbonate (or sodium hydroxide), stirring for extracting 1-5 times, laying aside for 1-10 hr, collecting deposit, dissolving in ether, eluting with the solution of dicarbonate or sodium hydroxide, regulating pH value, extracting in ether 1-3 times and recovering ether.
Description
Technical field
The present invention relates to a kind of Chinese herbal medicine extract, particularly a kind of from the Chinese medicine Olibanum method of effective component extracting; The invention still further relates to the purposes of this Olibanum extract and be suitable for the medicament of clinical use.
Background technology
The Chinese crude drug Olibanum has pharmacological action widely, experimental results show that Olibanum has promoting blood circulation and stopping pain, the effect of detumescence and promoting granulation.At present clinical how directly being used as medicine, cooperate other medicines treatment dysmenorrheas, amenorrhea, gastral cavity pain, rheumatic arthralgia, diseases such as traumatic injury and pain and ulcer sore pain with the fecula of Olibanum.Also often cooperating Myrrha to be used for the treatment of the skin infection diabrosis does not close up for a long time.Weak point is to make stomach weak person produce untoward reaction such as vomiting, goes into easily muddiness of decoct soup, is difficult to take.The Olibanum effective ingredient is carried out industrialization extract, be prepared into about can be used for clinical medicament with extract then, inquired into by the relevant expert for a long time.
Summary of the invention
One of purpose of the present invention provides a kind of method of the Olibanum effective ingredient being carried out the industrialization extraction; Two of purpose of the present invention provides the purposes of this Olibanum extract and is suitable for the medicament of clinical use.
One of purpose of the present invention can realize by following technical measures
It is raw material that the present invention adopts Olibanum (comprising Olibanum (processed)), earlier raw material powder is broken into 40～60 order coarser powder, put into extraction equipment, 60～95% the organic solvent lixiviate that adds 1～10 times of weight portion of raw material coarser powder, the control extraction temperature is 2～80 ℃, each extraction time is 1～48 hour, lixiviate 1～3 time, and lixiviating solution is condensed into extractum; The sodium hydroxide solution that adds 1～10% sodium bicarbonate solution or 1～5% to extractum is in normal temperature and pressure and stir extraction down 1～5 time, each 0.5～3 hour, after left standstill 1～10 hour, the collecting precipitation layer also dissolves with ether; Use 1～10% sodium bicarbonate solution, 1～5% sodium hydroxide solution gradient elution more respectively, transfer PH=2～6 then, ether is reclaimed in reuse ether extraction 1～3 time, gets Olibanum effective component extracts crude product.
One of purpose of the present invention also can realize by following technical measures
Olibanum effective component extracts crude product with dehydrated alcohol or acetone solvent recrystallization, is got Olibanum effective component extracts elaboration; Extraction temperature is 2～80 ℃, and each extraction time is 1～48 hour; Described organic solvent is ethanol, ether or petroleum ether.
Two of purpose of the present invention can realize by following technical measures
The Olibanum extract that the present invention extracts is used for antiinflammatory, the treatment rheumatic arthralgia.Olibanum extract is added proper auxiliary materials, make said various preparations on the pharmaceutics, wherein said preparation is meant oral formulations and injection.
Zoopery: getting body weight is 30 of 150～250g rats, and the male and female dual-purpose is divided into 3 groups immediately, 10 every group.Experimental group is irritated stomach respectively and is given Olibanum extract 0.5g/kg and 1g/kg body weight, and the normal control group is irritated stomach and given the equivalent normal saline, every day twice, continuous 7 days.Survey the left back pawl normal volume of every Mus with drainage.1h after the last administration respectively at the rat left and right sides rear solid end subcutaneous injection 0.2% histamine 0.1ml that stands on tiptoe, behind each measuring jaw volume of 0.5h, 1h, 2h, 4h and 6h 1 time, calculates the suppression ratio of Mus pawl swelling degree and experimental group then.Experimental result shows, Olibanum extract can be obviously pressed against swelling, had inflammatory effect due to the remarkable antihistamine rat foot due to the antihistamine.As shown in the table, its antiinflammatory action of 2～4h is the most obvious behind antiinflammatory.
Table:
| The left back pawl positive number of group dosage animal constant volume (ml) | Cause scorching back different time (h) paw swelling (ml) |
| 0.5??????????1????????????2?????????????4?????????????6 | |
| Matched group equivalent 10 0.94 ± 0.05 Olibanum group 0.5 10 0.91 ± 0.09 Olibanum group 1.0 10 0.96 ± 0.08 | 1.79±0.09???1.85±0.09???1.79±0.09????1.75±0.09????1.61±0.09 1.57±0.09???1.56±0.09???1.48±0.09????1.42±0.10????1.33±0.09 22.1％???????26.3％???????30.7％????????35.7％????????30.4％ 1.63±0.08???1.62±0.08???1.55±0.09????1.42±0.10????1.32±0.09 24.1％???????28.3％???????35.7％????????37.7％????????30.1％ |
Method of the present invention has solved that relevant technologies expert makes great efforts for a long time always and the problem about Chinese crude drug Olibanum extracts active ingredients that realization is not arranged, and this method can form industrial sectorization to the Olibanum extracts active ingredients.The present invention is the untoward reaction in capable of reducing using as the effective antiinflammatory medicine, avoids stomach weak person easily to cause vomiting, to go into the decoct soup easily muddy and defective such as be difficult to take, for new way has been opened up in the utilization of Olibanum effective ingredient.
The specific embodiment
Embodiment 1:
1, feeds intake: get Olibanum 20kg, be ground into 60 order coarser powder;
2, alcohol extraction: add 70% ethanol 35L the first time, controls 2 ℃ of temperature mercerations and carry 8 hours, adds 70% ethanol 100L for the second time, controls 50 ℃ of temperature, lixiviate 40 hours, and twice lixiviating solution merges, and gets lixiviate cream 4kg after concentrating recovery ethanol;
3, extraction: 8% sodium bicarbonate solution that adds 3 times of weight portions of extractum in extractum is in normal temperature and pressure and stir extraction down 5 times, each 1 hour, after left standstill collecting precipitation layer and with the ether dissolution of 0.5 times of weight portion of the beds of precipitation 2 hours; The 2% sodium bicarbonate solution gradient elution that adds 5% sodium hydroxide solution of 0.5 times of weight portion, 3 times of weight portions more respectively, with hydrochloric acid aqueous alkali layer pH value is adjusted to 5, and then to the ether that wherein adds 1 times of weight portion, extract repeatedly 3 times, reclaim ether, the gained extract is white or faint yellow precipitation.
4,, get Olibanum effective component extracts 1.2Kg with the extract acetone recrystallization.
Embodiment 2:
1, feeds intake: get Olibanum 20kg, be ground into 40 order coarser powder;
2, alcohol extraction: add 90% ether 180L for the first time, control 70 ℃ of temperature lixiviates 4 hours, add for the second time 80% ethanol 100L, control 40 ℃ of temperature, lixiviate 10 hours adds 70% ethanol 100L for the third time, control 10 ℃ of temperature, lixiviate 2 hours, three times lixiviating solution merges, and gets lixiviate cream 4kg after concentrating recovery ethanol;
3, extraction: 4% sodium hydroxide solution that adds 0.5 times of weight portion of extractum in extractum is in normal temperature and pressure and stir extraction down 3 times, each 2.5 hours, after left standstill collecting precipitation layer and with the ether dissolution of 3 times of weight portions of the beds of precipitation 9 hours; The 9% sodium bicarbonate gradient elution that adds 1% sodium hydroxide of 4 times of weight portions, 0.5 times of weight portion more respectively, with sulphuric acid aqueous alkali layer pH value is adjusted to 2, and then to the ether that wherein adds 3 times of weight portions, ether is reclaimed in the extraction back, and the gained extract is white or faint yellow precipitation.
4, extract is used the dehydrated alcohol recrystallization, got Olibanum effective component extracts 1.23Kg.
Embodiment 3:
1, feeds intake: get Olibanum 20kg, be ground into 50 order coarser powder;
2, alcohol extraction: add 90% petroleum ether 60L, control 70 ℃ of temperature lixiviates 4 hours, collect lixiviating solution, after concentrating recovery ethanol, get lixiviate cream 3.8kg;
3, extraction: 2% sodium hydroxide solution that adds 2 times of weight portions of extractum in extractum is in normal temperature and pressure and stir extraction down 1 time, each 1 hour, after left standstill collecting precipitation layer and with the ether dissolution of 2 times of weight portions of the beds of precipitation 5 hours; The 9% sodium bicarbonate gradient elution that adds 3% sodium hydroxide of 3 times of weight portions, 3 times of weight portions more respectively, with sulphuric acid aqueous alkali layer pH value is adjusted to 3, and then to the ether that wherein adds 2 times of weight portions, ether is reclaimed in the extraction back, and the gained extract is white or faint yellow precipitation.
4, extract is used the dehydrated alcohol recrystallization, got Olibanum effective component extracts 1.2Kg.
Embodiment 4:
Get Olibanum effective component extracts 600g, add microcrystalline Cellulose 100g, amylum pregelatinisatum 100g, carboxymethyl starch sodium 24g, Pulvis Talci 8g, magnesium stearate 8g make binding agent with dehydrated alcohol, are prepared into granule by the equivalent incremental method, and tabletting gets the Olibanum tablet.
Claims (7)
1, the Olibanum extraction process of effective component is characterized in that
A, elder generation are broken into coarser powder with frankincense powder, add 1～10 times of amount 60～95% organic solvent, lixiviate 1～3 time, and lixiviating solution gets extractum after concentrating;
B, add 1～10% sodium bicarbonate solution or 1～5% to extractum sodium hydroxide solution in normal temperature and pressure with stir extraction down 1～5 time, each 0.5～3 hour, after left standstill 1～10 hour, the collecting precipitation layer also dissolves with ether;
C, use 1～10% sodium bicarbonate solution, 1～5% sodium hydroxide solution gradient elution respectively again, transfer PH=2～6 then, ether is reclaimed in reuse ether extraction 1～3 time, Olibanum effective component extracts crude product.
2, Olibanum extraction process of effective component according to claim 1 is characterized in that Olibanum effective component extracts crude product with dehydrated alcohol or acetone solvent recrystallization, Olibanum effective component extracts elaboration.
3, Olibanum extraction process of effective component according to claim 1 is characterized in that extraction temperature is 2～80 ℃, and each extraction time is 1～48 hour.
4, Olibanum extraction process of effective component according to claim 1 is characterized in that described organic solvent is ethanol, ether or petroleum ether.
5, claim 1 or the 2 Olibanum effective component extracts that extract are used for antiinflammatory and treatment rheumatic arthralgia.
6, add proper auxiliary materials with claim 1 or the 2 Olibanum effective component extracts that extract, make said various preparations on the pharmaceutics.
7, the described preparation of claim 6 is meant oral formulations and injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410024253 CN1583063B (en) | 2004-06-10 | 2004-06-10 | Extraction of effective components from frankinscene and its preparation and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410024253 CN1583063B (en) | 2004-06-10 | 2004-06-10 | Extraction of effective components from frankinscene and its preparation and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1583063A true CN1583063A (en) | 2005-02-23 |
| CN1583063B CN1583063B (en) | 2012-03-28 |
Family
ID=34600853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410024253 Expired - Lifetime CN1583063B (en) | 2004-06-10 | 2004-06-10 | Extraction of effective components from frankinscene and its preparation and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1583063B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100569245C (en) * | 2005-06-02 | 2009-12-16 | 成都中医药大学 | The purposes of Olibanum in the medicine of preparation treatment gout |
| CN101775058B (en) * | 2009-01-08 | 2012-07-18 | 凌沛学 | Preparation and application of pharmaceutical preparation of 11-carbonyl-betal- acetyl mastic acid and derivatives thereof extracted from frankincense |
| CN102811728A (en) * | 2010-03-15 | 2012-12-05 | 莱拉营养食品有限公司 | Boswellia oil, its fractions and compositions for enhancing brain function |
| CN104703617A (en) * | 2012-09-21 | 2015-06-10 | 阿波卡-阿格里科拉共同股份公司 | New incense extract fractions and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5629351A (en) * | 1995-04-13 | 1997-05-13 | Council Of Scientific & Industrial Research | Boswellic acid compositions and preparation thereof |
-
2004
- 2004-06-10 CN CN 200410024253 patent/CN1583063B/en not_active Expired - Lifetime
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100569245C (en) * | 2005-06-02 | 2009-12-16 | 成都中医药大学 | The purposes of Olibanum in the medicine of preparation treatment gout |
| CN101775058B (en) * | 2009-01-08 | 2012-07-18 | 凌沛学 | Preparation and application of pharmaceutical preparation of 11-carbonyl-betal- acetyl mastic acid and derivatives thereof extracted from frankincense |
| CN102811728A (en) * | 2010-03-15 | 2012-12-05 | 莱拉营养食品有限公司 | Boswellia oil, its fractions and compositions for enhancing brain function |
| CN104703617A (en) * | 2012-09-21 | 2015-06-10 | 阿波卡-阿格里科拉共同股份公司 | New incense extract fractions and uses thereof |
| CN104703617B (en) * | 2012-09-21 | 2019-03-08 | 阿波卡-阿格里科拉共同股份公司 | New spice extract fraction and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1583063B (en) | 2012-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103446450B (en) | A kind of composition and method of making the same with alleviating physical fatigue function | |
| CN101292997B (en) | Pharmaceutical composition for treating empyrosis or gastric ulcer, and preparation method thereof | |
| CN101732668B (en) | Preparation method of Chinese medicinal composition for treating urinary system infection | |
| CN104983844A (en) | Edible composition formula with mucous-membrane restoring function and preparation process of preparation thereof | |
| CN1583063A (en) | Extraction of effective components from frankinscene and its preparation and use | |
| CN103272092A (en) | Huoxiang Zhengqi externally-applied preparation and its preparation method and application | |
| CN1887837A (en) | Extraction process and application of emodin and aloe-emodin | |
| CN100408058C (en) | Stomach-power Chinese medicine preparation and preparing method | |
| CN1256134C (en) | Medicinal composition for treating rheumatoid | |
| CN1212143C (en) | Medicine for treating coronary disease and its preparation method | |
| CN111714521B (en) | Periplaneta americana intestinal flora metabolite extract, preparation method thereof and application thereof in preparing anti-inflammatory or anti-ulcer products | |
| CN106421076B (en) | A kind of preparation method and application of bamboo willow bark anti-inflammatory activity extract | |
| CN101653488A (en) | Application of Chinese medicinal composition in preparation of medicament for resisting myocardial stunning | |
| CN1857706A (en) | Red flavonid and production process of its medicine composition | |
| CN107550996A (en) | A kind of CBS capsule of gastric acid secretion inhibiting and application | |
| US4447437A (en) | Pharmaceutical composition and method for treatment of peptic ulcer | |
| CN1045885C (en) | Method for preparing stomatitis spray | |
| CN101982186A (en) | Application of velvet bean extractive on preparing anti-inflammatory analgesic drug | |
| JP2821575B2 (en) | Liver disorder improving agent | |
| CN102499913A (en) | Preparation method for refined and purified paeonol preparation | |
| CN102210757B (en) | Application of Chinese medicine composition in preparation of medicine for treating coronary heart disease malignant arrhythmia | |
| CN1559447A (en) | Extracte of Aspongopus chinensis Dallas and Extraction method therefor medicinal use and preparn. thereof | |
| CN101342161A (en) | Application of frangula emodin, aloe-emodin in preparing anti-cerebral ischemia damnification medicament | |
| JPH0535131B2 (en) | ||
| CN112294855A (en) | Dispersible tablet for treating coronary heart disease and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Extraction of effective components from frankinscene and its preparation and use Effective date of registration: 20181213 Granted publication date: 20120328 Pledgee: CITIC Bank Limited by Share Ltd. Zibo branch Pledgor: SHANDONG QIDU PHARMACEUTICAL Co.,Ltd. Registration number: 2018370000224 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200426 Granted publication date: 20120328 Pledgee: CITIC Bank Limited by Share Ltd. Zibo branch Pledgor: SHANDONG QIDU PHARMACEUTICAL Co.,Ltd. Registration number: 2018370000224 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| CX01 | Expiry of patent term |
Granted publication date: 20120328 |
|
| CX01 | Expiry of patent term |